{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"35.7","upperLimit":"50.2","value":"42.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"}],"units":"Participants"}],"description":"Hematological assessments were performed from bone marrow biopsy samples. All hematological assessments of bone marrow were reviewed in a central reference laboratory.\n\nHematological remissions were defined by the following criteria:\n\nComplete Remission (CR):\n\n* bone marrow blasts ≤ 5%\n* no evidence of disease\n* full recovery of peripheral blood counts:\n\n  * platelets \\> 100,000/μL, and\n  * absolute neutrophil count (ANC) \\> 1,000/μL\n\nComplete Remission With Partial Hematological Recovery (CRh\\*):\n\n* bone marrow blasts ≤ 5%\n* no evidence of disease\n* partial recovery of peripheral blood counts:\n\n  * platelets \\> 50,000/μL, and\n  * ANC \\> 500/μL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"NUMBER","populationDescription":"The Primary Analysis Set (PAS), defined as participants from the first 3 stages of the study who received any infusion of blinatumomab.","reportingStatus":"POSTED","timeFrame":"Within the first 2 cycles of treatment, 12 weeks","title":"Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment","type":"PRIMARY","unitOfMeasure":"percentage of participants"}